The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Beck, Eduard J ^a,b,k   Mandalia, Sundhiya ^a,c,k   Sangha, Roshni ^a   Sharott, Peter ^d   Youle, Mike ^a,e   Baily, Guy ^f   Brettle, Ray ^g   Gompels, Mark ^h   Johnson, Margaret ^e   McCarron, Brendan ⁱ   Ong, Ed ^j   Pozniak, Anton ^k   Schwenk, Achim ^l   Taylor, Stephen ^m   Walsh, John ⁿ   Wilkins, Ed ^o   Williams, Ian ^p   Gazzard, Brian ^a,c,k  

^a NPMS HHC CIC   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d London Specialised Commissioning Group   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h SOUTHMEAD HOSPITAL   (United Kingdom)

ⁱ JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^j NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^k CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^l NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^m BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

ⁿ ST MARY S HOSPITAL   (United Kingdom)

^o NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG PROGRAM; DRUG USE; EARLY INTERVENTION; FEMALE; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; UNITED KINGDOM; COST BENEFIT ANALYSIS; DEMOGRAPHY; DRUG COMBINATION; ECONOMICS; HEALTH CARE DELIVERY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DEMOGRAPHY; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS;

EID: 83355170772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027830     Document Type: Article

References (28)

1. Beck EJ, Mandalia M, Lo G, Sharott P, Youle M, et al. (2011) Cost-effectiveness of early treatment with first-line NNRTI-based HAART Regimens in the UK, 1996-2006. PLoS ONE 6 (5): e20200 Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0020200. Accessed 14 November 2011.
2. UNAIDS/PEPFAR (2007) Interim Guidelines on Protecting the Confidentiality and Security of HIV information: Proceedings from a Workshop, 15-17 May 2006, Geneva, Switzerland. 15 May Available: http://data.unaids.org/pub/manual/2007/confidentiality_security_interim_guidelines_15may2007_en.pdf. Accessed 14 November 2011.
3. Beck EJ, Mandalia S, (2003) The Cost of HIV Treatment and Care in England since HAART: Part 1. British Journal of Sexual Medicine 27 (1): 19-21.
4. Beck EJ, Mandalia S, (2003) The Cost of HIV Treatment and Care in England since HAART: Part 2. British Journal of Sexual Medicine 27 (2): 21-23.
5. Mandalia S, Parmar D, Fisher M, Pozniak A, Tang A, et al. (2002) Naïvely Changing HAART. HIV Medicine 3: 254-262.
6. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, et al. (2004) The Cost-effectiveness of HAART, Canada 1991-2001. AIDS 18: 2411-9.
7. Badri M, Maartens G, Mandalia S, Bekker L-G, Penrod JR, et al. (2006) Cost-effectiveness of Highly Active Antiretroviral Therapy in South Africa. Plos Medicine January 3: e4.
8. Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, et al. (2008) Treatment Outcome and Cost-effectiveness of different HAART Regimens in the UK 1996-2002. International Journal of STD & AIDS 19: 297-304.
9. Beck EJ, Mandalia S, Mandalia R, Youle M, Gazzard B, (2010) Use and Cost of HIV Service Provision in UK NPMS-HHC Sites: Aggregate Analyses January 1996 to December 2006. NPMS-HHC Coordinating and Analytic Centre CIC, London, UK.
10. Beck EJ, Miners AH, (2001) Effectiveness and Efficiency in the Delivery of HIV Services: economic and related considerations. In: Gazzard B, Johnson M, Miles A, editors. The Effective Management of HIV Disease pp. 113-38 Aesculapius Medical Press, London.
11. Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH, (2005) Need for differential discounting of costs and health effect in cost-effectiveness analyses. BMJ 331: 446-8.
12. Rubin DB, (1987) Multiple Imputation for Nonresponse in Surveys New York John Wiley & Sons, Inc.
13. Schafer JL, (1997) Analysis of Incomplete Multivariate Data New York Chapman and Hall.
14. Thakkar B, Hur K, Henderson WG, Oprian C, (1998) A Method to Generate Kaplan-Meier and Adjusted Survival Curves using SAS. SUGI 23, Paper 226, March 22-25, Nashville, USA. Available: http://www2.sas.com/proceedings/sugi23/Stats/p226.pdf. Accessed 14 November 2011.
15. Rawlings MD, Culyer AJ, (2004) National institute for Clinical Excellence and its value judgements. BMJ 329: 224-227.
16. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group (2008) British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine 9: 563-608.
17. World Health Organization (WHO) (2010) Antiretroviral therapy for HIV infection in adults and adolescents, Recommendations for a public health approach, 2010 revision. Geneva, Switzerland. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 14 November 2011.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents (2011) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 November 2011.
19. Bajko MS, HIV study: 76% drop in cases with expanded treatment. Edge, San Francisco, California 18 April 2011 Available: http://www.edgesanfrancisco.com/index.php?ch=health_fitness&sc=health&sc2=news&sc3=&id=118575. Accessed 14 November 2011.
20. Neaton JD, Babiker A, Emery S, Gordin F, Lundgren J, et al. (2009) Strategic Timing of Antiretroviral Treatment (START) Available: http://clinicaltrials.gov/ct2/show/NCT00867048. Accessed 14 November 2011.
21. National Institutes of Health (NIH) News Treating HIV-infected People with Antiretrovirals Protects Partners from Infection: findings result from NIH-funded international study. National Institutes of Health 12th May 2011 Available: http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx. Accessed 14 November 2011.
22. Hankins CA, de Zalduondo BO, (2010) Combination prevention: a deeper understanding of effective HIV prevention. AIDS 2010 24 (suppl 4): S70-S80.
23. Beck EJ, Mays N, (2006) Some Lessons Learned. In: Beck EJ, Mays N, Whiteside A, Zugina J, editors. The HIV Pandemic: local and global implications Oxford University Press, Oxford, UK pp. 769-772.
24. Chadborn TR, Baster K, Delpech VC, Sabin CA, Sinka K, et al. (2005) No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 19: 513-520.
25. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG, (2006) The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006 20: 2371-2379.
26. Adler A, Mounier-Jack S, Coker RJ, (2009) Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 21: 284-293.
27. Health Protection Agency (2011) HIV in the United Kingdom: 2010 Report, Health Protection Report Volume 4 Number 47. Available: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287145367237. Accessed 14 November 2011.
28. Long E, Brandeau M, Owens D, (2010) The Cost-Effectiveness and Population outcomes of Expanded Screening and Antiretroviral Treatment in the US. Ann Inter Med 153: 778-89.